Drugmaker Agios Pharmaceuticals (NASDAQ: AGIO) is positioning to win the FDA's approval of its mitapivat as a treatment for sickle cell disease sooner than investors may have been expecting. That's the overarching takeaway from this morning's press release anyway. As it explains, Agios' recent meeting with the U.S. Food and Drug Administration laid the groundwork for the "submission of a proposal for a confirmatory clinical trial to support U.S. accelerated approval of mitapivat." The company's already su ...